These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 19122384)

  • 1. Telomerase-specific oncolytic virotherapy for human cancer with the hTERT promoter.
    Fujiwara T; Tanaka N
    Uirusu; 2008 Jun; 58(1):11-8. PubMed ID: 19122384
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Oncolytic virotherapy for human solid tumors].
    Fujiwara T
    Gan To Kagaku Ryoho; 2009 May; 36(5):703-9. PubMed ID: 19461167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Theranostic application of telomerase-specific oncolytic adenovirus for human cancer].
    Fujiwara T; Tanaka N
    Nihon Rinsho; 2007 Oct; 65(10):1913-22. PubMed ID: 17926546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic and therapeutic application of telomerase-specific oncolytic adenoviral agents.
    Fujiwara T; Urata Y; Tanaka N
    Front Biosci; 2008 Jan; 13():1881-6. PubMed ID: 17981675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Telomerase-specific oncolytic virotherapy for human cancer with the hTERT promoter.
    Fujiwara T; Urata Y; Tanaka N
    Curr Cancer Drug Targets; 2007 Mar; 7(2):191-201. PubMed ID: 17346111
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor effects of telomerase-specific replication-selective oncolytic viruses for adenoid cystic carcinoma cell lines.
    Sato D; Kurihara Y; Kondo S; Shirota T; Urata Y; Fujiwara T; Shintani S
    Oncol Rep; 2013 Dec; 30(6):2659-64. PubMed ID: 24065118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective metastatic tumor labeling with green fluorescent protein and killing by systemic administration of telomerase-dependent adenoviruses.
    Kishimoto H; Urata Y; Tanaka N; Fujiwara T; Hoffman RM
    Mol Cancer Ther; 2009 Nov; 8(11):3001-8. PubMed ID: 19887549
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Telomerase-specific replication-selective virotherapy for human cancer.
    Kawashima T; Kagawa S; Kobayashi N; Shirakiya Y; Umeoka T; Teraishi F; Taki M; Kyo S; Tanaka N; Fujiwara T
    Clin Cancer Res; 2004 Jan; 10(1 Pt 1):285-92. PubMed ID: 14734481
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic interaction of telomerase-specific oncolytic virotherapy and chemotherapeutic agents for human cancer.
    Fujiwara T; Kagawa S; Tazawa H
    Curr Pharm Biotechnol; 2012 Jul; 13(9):1809-16. PubMed ID: 21740362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo imaging of lymph node metastasis with telomerase-specific replication-selective adenovirus.
    Kishimoto H; Kojima T; Watanabe Y; Kagawa S; Fujiwara T; Uno F; Teraishi F; Kyo S; Mizuguchi H; Hashimoto Y; Urata Y; Tanaka N; Fujiwara T
    Nat Med; 2006 Oct; 12(10):1213-9. PubMed ID: 17013385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Telomerase-specific oncolytic virotherapy for human gastrointestinal cancer.
    Fujiwara T; Shirakawa Y; Kagawa S
    Expert Rev Anticancer Ther; 2011 Apr; 11(4):525-32. PubMed ID: 21504319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histone deacetylase inhibitor FR901228 enhances the antitumor effect of telomerase-specific replication-selective adenoviral agent OBP-301 in human lung cancer cells.
    Watanabe T; Hioki M; Fujiwara T; Nishizaki M; Kagawa S; Taki M; Kishimoto H; Endo Y; Urata Y; Tanaka N; Fujiwara T
    Exp Cell Res; 2006 Feb; 312(3):256-65. PubMed ID: 16356494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Understanding and exploiting hTERT promoter regulation for diagnosis and treatment of human cancers.
    Kyo S; Takakura M; Fujiwara T; Inoue M
    Cancer Sci; 2008 Aug; 99(8):1528-38. PubMed ID: 18754863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Visualization of intrathoracically disseminated solid tumors in mice with optical imaging by telomerase-specific amplification of a transferred green fluorescent protein gene.
    Umeoka T; Kawashima T; Kagawa S; Teraishi F; Taki M; Nishizaki M; Kyo S; Nagai K; Urata Y; Tanaka N; Fujiwara T
    Cancer Res; 2004 Sep; 64(17):6259-65. PubMed ID: 15342413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of oncolytic adenovirus and endostatin inhibits human retinoblastoma in an in vivo mouse model.
    Wang H; Wei F; Li H; Ji X; Li S; Chen X
    Int J Mol Med; 2013 Feb; 31(2):377-85. PubMed ID: 23229955
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo imaging of human cancer with telomerase-specific replication-selective adenovirus.
    Fujiwara T
    Methods Mol Biol; 2012; 872():129-39. PubMed ID: 22700408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo biological purging for lymph node metastasis of human colorectal cancer by telomerase-specific oncolytic virotherapy.
    Kojima T; Watanabe Y; Hashimoto Y; Kuroda S; Yamasaki Y; Yano S; Ouchi M; Tazawa H; Uno F; Kagawa S; Kyo S; Mizuguchi H; Urata Y; Tanaka N; Fujiwara T
    Ann Surg; 2010 Jun; 251(6):1079-86. PubMed ID: 20485131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intraperitoneal administration of telomerase-specific oncolytic adenovirus sensitizes ovarian cancer cells to cisplatin and affects survival in a xenograft model with peritoneal dissemination.
    Takakura M; Nakamura M; Kyo S; Hashimoto M; Mori N; Ikoma T; Mizumoto Y; Fujiwara T; Urata Y; Inoue M
    Cancer Gene Ther; 2010 Jan; 17(1):11-9. PubMed ID: 19662088
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel molecular therapy using bioengineered adenovirus for human gastrointestinal cancer.
    Fujiwara T
    Acta Med Okayama; 2011 Jun; 65(3):151-62. PubMed ID: 21709712
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-Time Fluorescence Image-Guided Oncolytic Virotherapy for Precise Cancer Treatment.
    Yano S; Tazawa H; Kishimoto H; Kagawa S; Fujiwara T; Hoffman RM
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33477279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.